Skip to main content

Evidence-Based Decision Making 7: Health Economics in Clinical Research

  • Protocol
  • First Online:
Clinical Epidemiology

Part of the book series: Methods in Molecular Biology ((MIMB,volume 2249))

  • 2482 Accesses

Abstract

The pressure for health-care systems to provide more resource-intensive health care and newer more costly therapies is significant, despite limited health-care budgets. As such, demonstration that a new therapy is effective is no longer sufficient to ensure that it is funded within publicly funded health-care systems. The impact of a therapy on health-care costs is also an important consideration for decision makers who must allocate scarce resources. The clinical benefits and costs of a new therapy can be estimated simultaneously using economic evaluation; the strengths and limitations of which are discussed herein. In addition, within this chapter, we discuss the important economic outcomes that can be collected within a clinical trial (alongside the clinical outcome data) enabling consideration of the impact of the therapy on overall resource use, thus enabling performance of an economic evaluation, if the therapy is shown to be effective.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Subscribe and save

Springer+ Basic
EUR 32.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or eBook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Protocol
USD 49.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 129.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 169.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 249.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Similar content being viewed by others

References

  1. Manns B, Taub K, Donaldson C (2000) Economic evaluation and end-stage renal disease: From basics to bedside. Am J Kid Dis 36:12–28

    Article  CAS  Google Scholar 

  2. United States Renal Data System (2013) Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the United States. https://www.usrds.org/atlas13.aspx. Accessed 17 Dec 2019

  3. Hirth RA (2007) The organization and financing of kindey dialysis and transplant care in the United States of America. Int J Health Care Finance Econ 7:301–318

    Article  Google Scholar 

  4. Manns BJ, Mendelssohn DC, Taub KJ (2007) The economics of end-stage renal disease care in Canada: incentives and impact on delivery of care. Int J Health Care Finance Econ 7:149–169

    Article  Google Scholar 

  5. Manns B, Hemmelgard B, Tonelli M et al (2019) The cost of care for people with chronic kidney disease. Can J Kid Health Dis 6:2054358119835521

    Google Scholar 

  6. Donaldson C, Shackley P, Detels R, Holland WW, McEwan J, Omenn GS (1997) Economic evaluation. Oxford Textbook of Public Health, 3rd edn. Oxford University Press, Oxford, pp 849–870

    Google Scholar 

  7. Manns B, Doig CJ, Lee H et al (2003) Cost of acute renal failure requiring dialysis in the intensive care unit: clinical and resource implications of renal recovery. Crit Care Med 31:449–455

    Article  Google Scholar 

  8. Johannesson M, Jonsson B, Kjekshus J, Olsson AG, Pedersen TR, Wedel H (1997) Cost effectiveness of simvastitin treatment to lower cholesterol levels in patients with coronary heart disease. Scand Simvastatin Survival Study Group. N Engl J Med 336:332–336

    Article  CAS  Google Scholar 

  9. Lee H, Manns B, Taub K et al (2002) Cost analysis of ongoing care of patients with end-stage renal disease: the impact of dialysis modality and dialysis access. Am J Kid Dis 40:611–622

    Article  Google Scholar 

  10. Klarenbach S, Tonelly M, Pauly R et al (2014) Economic evaluation of frequent home nocturnal hemodialysis based on a randomized controlled trial. J Am Soc Nephrol 25:587–594

    Article  Google Scholar 

  11. Chui BK, Manns B, Pannu N et al (2013) Health care costs of peritoneal dialysis technique failure and dialysis modality switching. Am J Kid Dis 61:104–111

    Article  Google Scholar 

  12. Dialysis modalities for the treatment of end-stage kidney disease: a health technology assessment. CADTH March 2017. https://cadth.ca/sites/default/files/pdf/OP0526_Dialysis_Modalities_Science_Report.pdf. Accessed 17 Dec 2019

  13. Fenton SS, Schaubel DE, Desmeules M et al (1997) Hemodialysis versus periotoneal dialysis: a comparison of adjusted mortality rates. Am J Kid Dis 30:334–342

    Article  CAS  Google Scholar 

  14. Foley RN, Parfrey PS, Harnett JD et al (1998) Mode of dialysis therapy and mortality in end-stage renal disease. J Am Soc Nephrol 9:267–276

    CAS  PubMed  Google Scholar 

  15. Bloembergen WE, Port FK, Mauger EA, Wolfe RA (1995) A comparison of mortality between patients treated with hemodialysis and periotneal dialysis. J Am Soc Nephrol 6:177–183

    CAS  PubMed  Google Scholar 

  16. Collins AJ, Hao W, Xia H et al (1999) Mortality risks of periotoneal dialysis and hemodialysis. Am J Kid Dis 34:1065–1174

    Article  CAS  Google Scholar 

  17. Gerard K, Mooney G (1993) QALY league tables: handle with care. Health Econ 2:59–64

    Article  CAS  Google Scholar 

  18. Mauskopf J, Rutten F, Schonfeld W (2003) Cost-effectiveness league tables: valuable guidance for decision maker? PharmacoEconomics 21:991–1000

    Article  Google Scholar 

  19. Drummond M, O’Brien B, Stoddart G, Torrance G (1997) Methods for the economic evaluation of health care programmes, 2nd edn. Oxford University Press, Oxford

    Google Scholar 

  20. Cameron C, Coyle D, Ur E, Klarenback S (2010) Cost-effectiveness of self-monitoring of blood glucose in patients with type 2 diabetes mellitus managed without insulin. Can Med Assoc J 182:28–34

    Article  Google Scholar 

  21. McIntosh B, Yu C, Lal A et al (2010) Efficacy of self-monitoring of blood glucose in patients with type 2 diabetes mellitus managed without insulin: a systematic review and meta-analysis. Open Med 4:e102–e113

    PubMed  PubMed Central  Google Scholar 

  22. McGhan WF, Al M, Doshi JA, Kamae I, Marx SE, Rindress D (2009) The ISPOR good practives for quality improvement of cost-effectiveness research task force report. Value Health 12:1086–1099

    Article  Google Scholar 

  23. Drummond MF, Jefferson TO (1996) The BMJ Economic Evaluation Working Party. Guidleines for authors and peer reviewers of economic submissions to the BMJ. Br Med J 313:275–283

    Article  CAS  Google Scholar 

  24. Gold R, Seigal J, Russell L, Weinstein M (1996) Cost-effectiveness in health and medicine. Oxford University Press, New York

    Google Scholar 

  25. Guidelines for the economic evaluation of health technologies: Canada (2017) 4th ed. Ottawa: CADTH

    Google Scholar 

  26. Donaldson C, Currie G, Mitton C (2002) Cost effectiveness analysis in health care: contraindications. Br Med J 325:891–894

    Article  Google Scholar 

  27. Laupacis A, Feeny D, Detsky AS, Tugwell PX (1992) How attractive does a new technology have to be to warrant adoption and utilization? Tentative guidelines for using clinical and economic evaluations. Can Med Assoc J 46:473–481

    Google Scholar 

  28. Schwappach DL (2003) Does it matter who you are or what you gain? An experimental study of preferences for resource allocation. Health Econ 12:255–267

    Article  Google Scholar 

  29. Shrive FM, Ghali WA, Lewis S, Donaldson C, Knudtson ML, Manns BJ (2005) Moving beyond the cost per quality-adjusted life year: modelling the budgetary impact and clinical outcomes associated with the use of sirolimus-eluting stents. Can J Cardiol 21:783–787

    PubMed  Google Scholar 

  30. Clement FM, Harris A, Li JJ, Yong K, Lee KM, Manns BJ (2009) Using effectiveness and cost-effectiveness to make drug coverage decisions: a comparison of Britain, Austrailia, and Canada. JAMA 302:1437–1443

    Article  CAS  Google Scholar 

  31. Miners AH, Garau M, Fidan D, Fischer AJ (2005) Comparing estimates of cost effectiveness submitted to the National Institue for Clinical Excellence (NICE) by different orgaisations: retrospective study. Br Med J 330:65

    Article  CAS  Google Scholar 

  32. O’Brien B (1996) Economic evaluation of pharmaceuticals. Frankenstein’s monster or vampire of tirals? Med Care 34(12 Suppl):DS99–D108

    PubMed  Google Scholar 

  33. Ramsey SD, Berry K, Etzioni R, Kaplan RM, Sullivan SD, Wood DE (2003) Cost effectiveness of lung-volume-reduction surgery for patients with severe emphysema. N Engl J Med 348:2092–2102

    Article  Google Scholar 

  34. Tonelli M, Klaarenback S, Jindal K, Manns B (2006) Economic implications of screening strategies in arteriovenous fistulae. Kidney Int 69:2219–2226

    Article  CAS  Google Scholar 

  35. Stelfox HT, Hemmelgarn BR, Bagshaw SM et al (2012) Intensive care unit bed availablity and outcomes for hospitalized patients with sudden clinical deterioration. Arch Intern Med 172:467–474

    Article  Google Scholar 

  36. Manns B, Owen WF Jr, Winkelmayer WC, Devereaux PJ, Tonelli M (2006) Surrogate markers in clinical studies: problems solved or created? Am J Kid Dis 48:159–166

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Braden J. Manns .

Editor information

Editors and Affiliations

Rights and permissions

Reprints and permissions

Copyright information

© 2021 Springer Science+Business Media, LLC, part of Springer Nature

About this protocol

Check for updates. Verify currency and authenticity via CrossMark

Cite this protocol

Manns, B.J. (2021). Evidence-Based Decision Making 7: Health Economics in Clinical Research. In: Parfrey, P.S., Barrett, B.J. (eds) Clinical Epidemiology. Methods in Molecular Biology, vol 2249. Humana, New York, NY. https://doi.org/10.1007/978-1-0716-1138-8_27

Download citation

  • DOI: https://doi.org/10.1007/978-1-0716-1138-8_27

  • Published:

  • Publisher Name: Humana, New York, NY

  • Print ISBN: 978-1-0716-1137-1

  • Online ISBN: 978-1-0716-1138-8

  • eBook Packages: Springer Protocols

Publish with us

Policies and ethics